Immix Biopharma (IMMX) Operating Expenses (2021 - 2026)

Immix Biopharma has disclosed Operating Expenses across 6 years of filings, most recently posting $10.8 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $10.8 million, up 130.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.1 million (up 65.74% YoY), and the FY2025 annual result was $30.0 million, up 32.11% from the prior year.
• Operating Expenses came in at $10.8 million for Q1 2026 at Immix Biopharma, down from $10.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $10.9 million in Q4 2025 to a low of $1.3 million in Q1 2022.
• The 5-year median for Operating Expenses is $4.7 million (2024), against an average of $5.2 million.
• Across the five-year window, Operating Expenses jumped 718.38% in 2022 and dropped 16.23% in 2025, its largest moves.
• Immix Biopharma's Operating Expenses stood at $3.8 million in 2022, then surged by 41.67% to $5.4 million in 2023, then fell by 7.23% to $5.0 million in 2024, then jumped by 118.43% to $10.9 million in 2025, then decreased by 0.82% to $10.8 million in 2026.
• The last three Operating Expenses figures came in at $10.8 million (Q1 2026), $10.9 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.